0
Original Research: COPD |

Efficacy of Aclidinium Bromide 400 μg Twice Daily Compared With Placebo and Tiotropium in Patients With Moderate to Severe COPDEfficacy of Aclidinium bid in Patients With COPD

Rainard Fuhr, MD, PhD; Helgo Magnussen, MD; Kristina Sarem, MD; Anna Ribera Llovera, PharmD, PhD; Anne-Marie Kirsten, MD; Meritxell Falqués, MS; Cynthia F. Caracta, MD, FCCP; Esther Garcia Gil, MD
Author and Funding Information

From PAREXEL International GmbH (Drs Fuhr and Sarem), Berlin, Germany; Pulmonary Research Institute at Hospital Grosshansdorf (Drs Magnussen and Kirsten), Grosshansdorf, Germany; Almirall, SA (Ms Falqués and Drs Ribera Llovera and Garcia Gil), Barcelona, Spain; and Forest Research Institute, Inc (Dr Caracta), Jersey City, NJ.

Correspondence to: Rainard Fuhr, MD, PhD, Early Phase Clinical Unit–Berlin, Parexel International GmbH, Klinikum Westend-Haus 31, Spandauer Damm 130, 14050 Berlin, Germany; e-mail: Rainard.Fuhr@parexel.com


Funding/Support: This work was funded by Almirall, SA, in collaboration with Forest Research Institute, Inc, a wholly owned subsidiary of Forest Laboratories, Inc.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).


© 2012 American College of Chest Physicians


Chest. 2012;141(3):745-752. doi:10.1378/chest.11-0406
Text Size: A A A
Published online

Background:  The efficacy and safety of aclidinium bromide bid, a novel, long-acting, muscarinic antagonist, was assessed in patients with moderate to severe COPD.

Methods:  In this phase IIa randomized, double-blind, double-dummy, crossover trial, patients with moderate to severe COPD received aclidinium 400 μg bid, tiotropium 8 μg once daily, and placebo for 15 days, with a 9- to 15-day washout between treatment periods. Treatments were administered through the Genuair or HandiHaler dry powder inhalers. The primary end point was mean change from baseline in FEV1 AUC0-12/12h (area under the curve where the numbers represent the time period for which data were collected divided by the number of hours over which the data are averaged [eg, 0-12 h postdose divided by 12 h]) on day 15. Secondary end points were changes from baseline in FEV1 AUC12-24/12h, FEV1 AUC0-24/24h, morning predose FEV1, peak FEV1, and COPD symptom scores.

Results:  Thirty patients with COPD were randomized, and 27 completed the study. Mean change from baseline in FEV1 AUC0-12/12h at day 15 was significantly greater for aclidinium and tiotropium over placebo (P < .0001). Mean changes from baseline in FEV1 AUC12-24/12h, FEV1 AUC0-24/24h, morning predose FEV1, and peak FEV1 at day 15 were significantly greater for aclidinium and tiotropium over placebo (P < .0001 for all except P < .001 for FEV1 AUC12-24/12h tiotropium vs placebo). Improvements were significantly greater with aclidinium vs tiotropium on day 1 for all of the normalized AUC values of FEV1 as well as on day 15 for FEV1 AUC12-24/12h (P < .05 for all). COPD symptoms were significantly improved from baseline with aclidinium vs placebo (P < .05) but not with tiotropium.

Conclusions:  In patients with COPD, aclidinium 400 μg bid compared with placebo provided clinically meaningful improvements in 24-h bronchodilation that generally were comparable to tiotropium 18 μg daily but with significant differences in favor of aclidinium observed in the average nighttime period. Larger studies with longer treatment duration are ongoing to confirm the efficacy of aclidinium 400 μg bid on bronchodilation and COPD symptoms.

Trial registry:  ClinicalTrials.gov; No.: NCT00868231; URL: www.clinicaltrials.gov.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543